Table 1.
Patient Characteristics
| Overall (N=31) | FOLFOX (N=11) | FOLFIRI (N=20) | |
|---|---|---|---|
| Age, years | |||
| Median | 59 | 68 | 55.5 |
| Range | 50–73 | 59–72 | 50–73 |
| ≥65 | 11 (35.5%) | 7 (63,6%) | 4 (20%) |
| ECOG-PS | |||
| 0 | 16 (51.6%) | 7 (63.6%) | 9 (45%) |
| 1 | 15 (48.4%) | 4 (36.4%) | 11 (55%) |
| Sex | |||
| Male | 19 (61.3%) | 5 (45.5%) | 14 (70%) |
| Female | 12 (38.7%) | 6 (54.5%) | 6 (30%) |
| Site of metastatic disease | |||
| Liver | 19 (61.3%) | 6 (54.5%) | 13 (65%) |
| Lung | 6 (19.3%) | 3 (27.2%) | 3 (15%) |
| Peritoneum | 4 (12.9%) | 2 (18.2%) | 2 (10%) |
| Others | 2 (6.4%) | 1 (9.1%) | 1 (5%) |
| Number of metastatic sites | |||
| 1–2 | 19 (61.3%) | 6 (54.5%) | 12 (60%) |
| ≥3 | 13 (41.9%) | 5 (45.5%) | 8 (40%) |
| Carbohydrate antigen 19–9 — U/mLa | |||
| Median | 934 | 1523 | 450 |
| Range | 14–13,027 | 521–7295 | 14–13,027 |
| Previous treatment | |||
| Radiation therapy | 1 (3.2%) | 0 | 1 (5%) |
| Surgery | 4 (12.9%) | 0 | 4 (20%) |
| Biliary stent | 7 (22.6%) | 0 | 7 (35%) |
| Pain | |||
| Yes | 16 (51.6%) | 4 (36.4%) | 12 (60%) |
| Previous NabGem | |||
| Median PFS months (95%CI) | 6 (4–7) | 5 (3–5) | 6 (4–8) |
| PFS >3 months | 22 (71%) | 6 (54.5%) | 16 (80%) |
| >4 cycles of NabGem | 7 (71%) | 6 (54.5%) | 1(15%) |
Note: aUnit of measure.